Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00149851 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 832
- Enrollment target
NCT00149851 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 832 participants.
The verdict
NCT00149851, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 832 participants
- Enrollment target
Study Summary
Gastroesophageal Reflux Disease (GERD) is a common disorder caused by the reflux of gastric (stomach) acid into the esophagus. The exposure of the lining of the esophagus to the acid will cause damage to the esophagus over time. The symptoms of GERD include heartburn and acid regurgitation This study will determine if Tegaserod alone and in combination with omeprazole is safe and relieves the symptoms of heartburn.
Interventions
- DRUG Tegaserod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 832 participants |
| Start Date | 2004-01 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00149851
The ClinicalTrials.gov registry entry for NCT00149851 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 832 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tegaserod is the first listed.
NCT00149851 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00149851 about?
NCT00149851 is a clinical study titled "A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)". Gastroesophageal Reflux Disease (GERD) is a common disorder caused by the reflux of gastric (stomach) acid into the esophagus. The exposure of the lining of the esophagus to the acid will cause damage to the esophagus over time. The symptoms of GERD include heartburn and acid regurgitation This stud...
What is the current status of trial NCT00149851?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 832 participants. The study started on 2004-01. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00149851?
The interventions under investigation include: Tegaserod (DRUG).
Who is sponsoring clinical trial NCT00149851?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.